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Abstract
Background: Splinting as part of the overall post-surgical management of patients after release of
Dupuytren's contracture has been widely reported, though there is variation in practice and criteria
for using it. The evidence on its effectiveness is sparse, of poor quality and contradictory with
studies reporting negative and positive effects.
Methods/Design: A multi-centre, pragmatic, randomized, controlled trial is being conducted to
evaluate the effect of static night splinting for six months on hand function, range of movement,
patient satisfaction and recurrence at 1 year after fasciectomy or dermofasciectomy. Using a
centrally administered computer randomization system consented patients will be allocated to one
of two groups: i) splint group who will be given a static splint at approximately 10 to 14 days after
surgery to be worn for 6 months at night time only as well as hand therapy; ii) non-splint group,
who will receive hand therapy only. The primary outcome measure is the patient-reported
Disabilities of the Arm, Hand and Shoulder Questionnaire (DASH). Secondary outcomes are total
active flexion and extension of fingers, patient satisfaction and recurrence of contracture. Outcome
measures will be collected prior to surgery, 3 months, 6 months and 1 year after surgery. Using
the DASH as the primary outcome measure, where a difference of 15 points is considered to be a
clinically important difference a total of 51 patients will be needed in each group for a power of
90%. An intention-to-treat analysis will be used.
Discussion: This pragmatic randomized controlled trial will provide much needed evidence on the
clinical effectiveness of post-operative night splinting in patients who have undergone fasciectomy
or dermofasciectomy for Dupuytren's contracture of the hand.
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Dupuytren's Disease
Dupuytren's Disease (DD) is a progressive fibroprolifera-
tive disorder of the palmar fascial complex of the hand.
Fascial bands form nodules and cords and eventually con-
tract causing digital finger flexion contractures where they
cross joints, especially in the metacarpophalangeal (MCP)
and proximal interphalangeal (PIP) joints of the fingers.
The little and ring fingers are most frequently affected.
These contractures can lead to severe impairments in hand
function[1]. Prevalence is highest in people of Northern
European stock. The disease presents most commonly in
men in their 5th decade of life and an estimated 20% of
men over the age of 60 years are affected. In the UK more
than 2 million people have DD many of which will
require surgical intervention[1].
Surgical and post-surgical management
Although pharmacological treatment options are being
investigated[2], transection of cords (fasciotomy) or exci-
sion of diseased fascial bands (fasciectomy) with or with-
out excision of overlying skin remain the only treatments
at present [1,3]Surgery is designed to reverse digital con-
tractures and to restore hand function vital for everyday
activities of self-care, work and leisure[4]. Following sur-
gery hand therapy provided by specialist occupational
therapists or physiotherapists is seen as integral to the
management of these patients and is aimed at reducing
swelling, optimising wound healing, restoring finger
mobility and maximising hand function[4]. In order to
maintain the optimum finger extension achieved through
surgical release some surgeons advocate the use of static or
dynamic splints for daytime and/or night time to be worn
up to 6 months. The aim of the splint is to provide pro-
longed stretch to healing tissues and prevent flexion con-
tractures. Whilst the effectiveness of surgical excision is
well established the benefit of different post-operative
interventions including static splinting and their effect on
functional outcomes remain undecided.
Evidence on effectiveness of splinting is low quality and 
inconclusive
Surveys of practice among hand surgeons [5] have high-
lighted wide variation in the use of post-operative splints
[6,7], largely due to a lack of good quality evidence to sup-
port their use.
The evidence that does exist regarding post-operative
splinting is inconsistent reporting both negative [8](loss
of finger flexion, delayed return to function and increased
recurrence) and positive (improved scar extendibility,
reduced finger extension deficits and delayed recur-
rence)[9] effects. Research to date is inconclusive due to
the available studies being observational, small scale and
heterogeneous in terms of the interventions (i.e. type of
splint and wearing regimens) and assessment of out-
comes.
The need for a trial
Severe Dupuytren's contracture requiring release accounts
for approximately 12,000 patients undergoing surgery in
the UK per year [10]. Despite the fact that evidence on the
effectiveness of post-operative interventions including
splinting remains scarce it remains widely used in prac-
tice. A recent survey of 573 orthopaedic consultants in the
UK showed that 33% of surgeons used splinting most or
all of the time [7]. Another UK survey of 141 surgeons of
various grades found that 84% advocated the use of a ther-
moplastic night splint, however duration of wear differed
widely ranging from a few weeks to 6 months[6].
Custom-made splints are costly in terms of material and
therapists' time to fabricate. For the patient they may be
cumbersome and inconvenient to wear even if only at
night-time, which in turn may affect adherence. Also,
there is some controversy over the amount of tension [11]
and the effect of tension on diseased fascia with some in
vitro studies indicating that this can accelerate the fibro-
proliferative turnover, possibly speeding up recurrence
and extension of contractures[12].
On the other hand there is also evidence that they may
help in maintaining extension of digits especially where
the PIP joint is involved. The rationale for using splints is
that they provide continuous low-load tension to healing
tissues and thus help to elongate scar tissue[11], which
other modalities such as active and passive hand exercises
can also achieve but which can be time-consuming for
patient and therapists. In the absence of any high quality
evidence to support post-operative splints their wide-
spread use may no longer be justifiable to purchasers, pro-
viders or patients.
Methods
Objectives of the trial
To compare the effectiveness of post-operative static night
splinting additionally to standard post-operative hand
therapy in improving patient reported hand function,
total active movement, patient satisfaction and recurrence
at one year.
Design
The randomized controlled trial is an accepted methodol-
ogy for minimizing potential biases and ensuring high
internal validity. This study is a pragmatic, multi-centre,
randomized controlled trial comparing two interventions:
post-operative hand therapy including a static night splint
versus post-operative hand therapy without splint.Page 2 of 5
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The trial will recruit patients from five National Health
Services teaching hospitals across three regions in East
Anglia in the UK. All five centres have an orthopaedic serv-
ice and two centres also include a plastic and reconstruc-
tive surgery service making up a total of 15 orthopaedic
and plastic surgeons with an interest in hand surgery who
regularly undertake fasciectomy and/or dermofasciec-
tomy for Dupuytren's contracture (DC). Post-surgical
hand rehabilitation services are provided at each centre by
hand therapists (occupational therapists and/or physio-
therapists with a special interest in hand injuries). Patients
admitted for surgery are either operated on as day-cases or
admitted overnight, depending on the extent of surgical
excision and overall health status.
Ethics
This multi-centre trial was approved by the Research Eth-
ics Committees and Research Governance Committees for
each participating hospital. Informed, written consent
will be obtained from all patients prior to enrolment into
the trial.
Recruitment
Patients referred to the orthopaedic and plastic surgery
out-patient clinics with a Dupuytren's contracture will be
assessed and screened for eligibility by the consultant sur-
geons. Those meeting inclusion criteria will be told about
the trial and given an information leaflet to take away
with them. The waiting times between listing for surgery
and actual surgery ranges from 12 to 22 weeks, therefore
recruitment and consent will be collected later and closer
to the date of surgery. Six to eight weeks prior to surgery
patients are sent a full participant information sheet and a
consent form with a self-addressed envelope by the trial
co-ordinator. Those returning a signed consent form are
contacted to arrange a pre-surgical baseline assessment.
Inclusion and exclusion criteria
The target study population are patients with Dupuytren's
disease affecting one or more fingers presenting at hand
clinic requiring surgical release by fasciectomy or dermo-
fasciectomy and who have consented to surgery. Exclu-
sions are: patients under the age of 18 years, those unable
to give informed consent and patients with Dupuytren's
contracture affecting the first web space only.
Randomization
Patients will be randomized into one of two groups. One
group will receive post-operative hand therapy only and
the other group will receive hand therapy and a static
night splint to be worn for 6 months. Randomization will
be stratified by recruiting hospital (5 centres) and surgical
procedure (dermofasciectomy or fasciectomy) in block
lengths of 4.
Patients are randomized after surgery. This will ensure
operating surgeons are unaware of group allocation at the
time of surgery. A telephone based central computerised
randomization service will be used to generate the alloca-
tion sequence and the treating hand therapists will obtain
the group allocation just before or at the first post-opera-
tive hand therapy appointment by ringing a dedicated tel-
ephone number available 24 hours. Neither the patients
nor the treating hand therapists can be blinded to group
allocation.
Interventions
Surgical procedure, that is approach and extent of surgical
excision as well as post-operative hand therapy, will not
be standardised. Surgeons vary in their preference and
skill for different procedures and it is difficult to standard-
ise these. Immediate post-operative management includ-
ing the use of plaster of Paris or thermoplastic resting
splints, type of dressing and time to removal of sutures
varies between surgeons and centres. Local standard pro-
tocols will be followed. For the purposes of this trial the
intervention period commences at the first hand therapy
appointment which is normally after suture removal (7–
14 days after surgery). Hand therapy will be tailored to the
patients presenting problems and needs and is aimed at
reducing oedema, promoting wound healing and guiding
post-surgical scarring, maximising finger range of move-
ment and facilitating full return to functional use of the
hand. This can be achieved through a wide range of
modalities. The hand therapists who deliver the treatment
will use a standard checklist to record the number of ses-
sions each patient receives as well as the modalities and
treatments received at each session.
Splint group
The use of a static night splint is standard practice in all 5
participating centres for the majority of patients, conse-
quently the provision of the night splint in this trial does
not constitute a new intervention. Therapists already have
training and experience in manufacturing custom-made
splints for DC and local protocols and procedures regard-
ing choice of material and design will be followed. Splints
will be static with no dynamic components. The principle
of 'no tension' ([11,13]will be used. This involves placing
the operated digits in maximum achievable extension
without placing tension on the surgical wound. Any non-
correctable contractures at the time of surgery will be
accommodated in the splint.
Where splints are contra-indicated, for example due to
post-surgical complications, the application of the splint
is delayed. Patients allocated to the splint group will be
asked to wear splints at night-time only for 6 months.
They are given a simple splint diary in which they record
on a weekly basis how many nights out of 7 they actuallyPage 3 of 5
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diary will be collected at the 3 months and 6 months fol-
low-up visit by the research associates.
No splint group
Patients allocated to the no-splint group will receive hand
therapy as described above only. During the early post-
operative phase and especially where the surgical scar
crosses the metacarpophalangeal (MCP) or interphalan-
geal (IP) joints patients may experience loss of extension
due to the tendency of scar tissue to contract. Such a loss
of finger extension may be temporary and also may
respond to other treatment modalities such as active exer-
cises, scar massage etc., however where this does not
resolve within a week and exceeds an acceptable threshold
patients will be given a splint. The criteria for such proto-
col deviations have been devised and agreed by all partic-
ipating centre surgeons and therapists. The first hand
therapy visit after surgery will be used to record baseline
active extension at MCP and proximal interphalangeal
(PIP) joints. On subsequent visits this is reassessed and if
loss of extension compared to this baseline is greater than
20° at the PIP joint or greater than 30° at the MCP joint
patients will be given a splint. Protocol deviations and
reasons for these will be recorded.
Outcomes
Surgical release of a Dupuytren's contracture is primarily
designed to 'open up' the palm and restore finger extensi-
bility and improve hand function. Past studies of
splinting have reported outcomes in terms of total active
extension and total active flexion as well as self-reported
symptoms, function and disability.
The primary outcome measure is self-reported hand func-
tion and disability assessed by the Disabilities of Arm
Shoulder and Hand Questionnaire (DASH)[14]. The
DASH is a 30-item patient-reported questionnaire
designed to measure, symptoms and physical function in
patients with musculoskeletal disorders of the upper
extremity. There is no disease-specific outcome instru-
ment for Dupuytren's contracture and the validation of
the DASH has been done on a wide range of patients
including Dupuytren's contracture. Longitudinal con-
struct validity has been assessed in patients including
those with DC and the responsiveness assessed by effect
size is moderate (ES = 0.5). It has good concurrent validity
with the subscales of the SF-36 [15] and test-retest reliabil-
ity has been found to be excellent (ICC = 0.96) [16].
Secondary outcomes are range of movement, patient sat-
isfaction and recurrence. Range of movement for digits I
to IV will be assessed using a Rolyan hyperextension finger
goniometer and following a standardised protocol. Total
active flexion (TAF) and total active extension (TAE) will
be recorded by adding individual DIP, PIP and MCP joint
scores. Intra-tester reliability of finger goniometry using a
standardised protocol has been shown as acceptable [17]
with a within-tester error of less than 5 degrees.
Patient satisfaction will be assessed at 6 and 12 months
using an 11 point verbal rating scale (VRS) with the ques-
tion: How satisfied are you with the overall result of the
surgery now? A score of 0 means completely dissatisfied
and 10 means completely satisfied.
Recurrence of contracture in the previously operated field
[10] will be assessed only at 6 months and 12 months
post surgery by MCP and PIP joint extension deficit.
Baseline data on socio-demographic variables (including
age, gender, handedness, previous surgery and occupa-
tional status) will be collected at the pre-operative
appointment together with RoM measurements and
DASH questionnaire. A number of other measures will be
obtained: patients allocated to the splint group will be
asked to keep a splint diary to measure splint adherence.
Frequency and type of treatment received by the hand
therapists will be recorded.
Timing of outcome measures
Baseline assessment will occur at 4 to 8 weeks prior to sur-
gery. Follow-up assessments at 3 months, 6 months and 1
year post-surgery as well as baseline assessment will be
taken by the research associates employed on the trial.
Patients will be visited at home in order to measure finger
range of movement with a finger goniometer using a
standardised protocol and collect the completed DASH
Questionnaire which is posted out prior to the visit. At the
6 months and 12 months follow-up visit the verbal rating
scale for satisfaction will also be administered and the
presence or absence of recurrence in contracture (as dis-
tinct from scar or joint contracture) will be assessed. The
patient completed splint dairy will also be collected at 3
months and 6 months and the patient asked to rate their
overall adherence with splint wear as an average propor-
tion out of 7 days.
Blinding
Due to the nature of this study, it is not possible to blind
the patient or the treating therapist to the intervention
received. The primary outcome measure is the patient-
rated DASH and therefore blinded assessment is not pos-
sible. Secondary outcomes will be assessed by research
associates who will not be blinded to the group alloca-
tion.
Sample size
Using the DASH [14] as the primary outcome measure,
where a difference of 15 points is considered to be a clin-Page 4 of 5
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group standard deviation of 22 points [18] a total of 51
patients would be needed in each group for a power of
90%. Allowing for a 20% loss to follow-up a total of 128
patients need to be randomized. Based on current surgery
rates in the five participating centres and assuming a con-
sent rate of 40–50% of those patients invited to take part
we anticipate that the target sample size can be recruited
within 16 months.
Analysis strategies
All analyses will be conducted using an Intention-to-treat
approach using all randomized participants. The primary
endpoint is assumed to follow a Normal distribution.
Mean scores between groups at follow-up will be analysed
using a general linear model with baseline DASH scores as
a covariate and hospital and type of surgery also added as
independent factors (these are used to stratify the rand-
omization).
Range of movement and satisfaction will be similarly ana-
lysed. However, as multiple digits are likely to be involved
per person, a generalised estimating equation (with a Nor-
mal error term) will be used to adjust for intra-person cor-
relations. The proportion of individuals with recurrent
DD will be compared between groups and analysed using
Fisher's Exact test. Subgroup analyses will be undertaken
by adding an appropriate interaction term to the general
linear model or general estimating equation. An interac-
tion between group and severity and group and type of
surgery will be considered, i.e. a subgroup analysis of
severity and type of surgery. It is acknowledged that the
statistical power of such analyses is likely to be low but as
these are of secondary concern it would be inappropriate
to consider a potentially very large sample size increase
simply on account of these.
Discussion
This pragmatic randomised controlled trial will provide
much needed evidence on the clinical effectiveness of
post-operative night splinting in patients who have under-
gone fasciectomy or dermofasciectomy for DC.
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